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ABStrACt 
 
Introduction: Cervical cancer is one of the most common diseases among women, and cause considerable morbidity and mortality. 
Considering that cervical cancer is an important neoplasia in northeastern Brazil, and the prevalence of high-risk human papillomavirus 
(HPV) is directly associated with it, this work had aimed to correlate the cytological and/or colposcopic findings with HPV infection status, 
and verify the performance of MY09/MY11 and GP5+/6+ primers for HPV detection. Material and method: Patients in this study were 
from Penedo-AL, a city with high level of poverty (poverty rate of 60.62%). Out of 70 patients with cytological and/or colposcopic changes, 
32 agreed to participate in the study. Results: Regarding cytology, 21 (30%) patients presented atypical squamous cells of undetermined 
significance (ASC-US); 20 (29%), atypical glandular cells of undetermined significance (AGUS); 12 (17%), low-grade intraepithelial lesion 
(LSIL); five (7%), high-grade intraepithelial lesion (HSIL); and 12 (17%), positive colposcopy. From these, 27 (84%) presented the band 
gene encoding for human ß-globin. From the 27 patients, eight (30%) were positive for HPV. The results showed that the deoxyribonucleic 
acid (DNA) of HPV was detected in 15% and 30% by using MY-PCR and GP +-PCR, respectively. Conclusion: This study suggests that more 
than one type of oligonucleotide primer should be used in clinical samples to increase sensitivity for the detection of HPV.
Key words: cervical cancer; cytology; colposcopy; HPV; PCR.
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introDuCtion
Cervical cancer is one of the most common diseases among 
women, and causes considerable morbidity and mortality. 
According to Globocan (2008), 188 thousand new cases occur 
annually in Asia, 134 thousand in India, 75 thousand in Africa, 
and 24 thousand in Brazil. In developed countries, such as the 
United States of America, the incidence was 11 thousand, and in 
the European Union was 31 thousand(10). 
Cervical cancer mortality worldwide is 275 thousand, and 242 
thousand occurred in less developed regions. In Brazil, cervical 
cancer mortality is still high, with 110 thousand deaths(2). The 
differences in incidence and mortality between developed and 
developing countries may be due to regional differences, prevalence 
and distribution of major risk factors, practices of detection and/or 
availability and use of treatment services(1). 
Epidemiological and molecular studies have shown close link 















cancer, as well as its precursors lesions, implying that the virus 
presence is a cancer-causing agent(7, 28). Walboomers et al.(26), 
using the polymerase chain reaction (PCR) and serological tests, 
showed that HPV is present in 99.7% of patients with invasive 
cervical cancer.
Molecular diagnosis of HPV infection is important for virus 
screening, and is mainly based on methods such as: hybrid 
capture (CH2)(20, 23), in situ hybridization(2), and PCR(8, 21, 24). These 
techniques have vary widely in terms of sensitivity and specificity, 
and PCR is the most used today in various areas of molecular 
diagnostics due to its great ability to detect small fragments of 
deoxyribonucleic acid (DNA)(4, 11).
The system uses MY09/MY11 and GP5+/GP6+ primers, that 
amplify the L1 region of viral genome, are more frequently used for 
HPV detection in clinical and histological studies(12). These primers 
are effective for amplifying wide spectrum of HPV genotypes 
in cells obtained from cervical smears and paraffin-embedded 
tissues(13, 16). The pair of oligonucleotides MY09/MY11 primers 
flanks a sequence of approximately 450 pb, while the pair GP5+/
GP6+, a sequence of approximately 150 pb, which is internal to 
the sequence flanked by MY(22). The pair MY is synthesized from 
several degenerate nucleotides in each primer, it is a mixture of 
25 primers oligonucleotides able to amplifying > 25 genital HPV 
types. On the other hand, the pair GP5+/GP6+ consists of a fixed 
sequence of nucleotide for each oligonucleotide primer. This pair 
uses low annealing temperature during PCR(18), and may be used 
as a single oligonucleotide primer or in PCR “nested”, after the MY 
oligonucleotide primer amplification(9).
This study aimed to investigate HPV infection in women with 
cytological and/or colposcopic abnormalities, which were seen in 
a poor city of Alagoas, and also verify the performance of MY09/
MY11 and GP5+/GP6+ primers for HPV detection.
 
MAtEriAL AnD MEthoD
This is a cross-sectional study, performed during May 2009 
to March 2011, from epidemiological data on cytological and/or 
colposcopic abnormalities cases diagnosed at Clinic of Gynecology 
of Núcleo de Apoio à Saúde da Família (NASF) in Penedo-Alagoas, 
city with high poverty (60.62%)(14).
The study included women had as cytological result: atypical 
squamous cells of undetermined significance (ASC-US), atypical 
glandular cells of undetermined significance (AGUS), low-grade 
intraepithelial lesion (LSIL), high-grade intraepithelial lesion 
(HSIL), and invasive carcinoma. Patients with colposcopic 
changes such as acetowhite epithelium (AWE), dotted, mosaic, 
partial iodine-positive epithelium and iodine-negative epithelium, 
classified as positive colposcopy, were also included in this study. 
Patients’ data were obtained from medical records. Cervical 
samples were only collected from patients who signed the Informed 
Consent. This project was approved by Research Ethics Committee 
of Universidade Tiradentes, Aracaju-SE.
Cervical smears were collected using Ayre spatula, then placed 
in Falcon tubes, with 25 ml of PBS buffer solution (phosphate-
buffered saline, pH 7.4), and stored at -20ºC until DNA extraction.
 
DNA extraction
DNA extraction from cervical smears was performed using 
QIAamp DNA Mini Kit (QiagenLtd, Crawley, UK), according to 
manufacturer’s instructions. Aliquots of 200 μl of samples were 
digested with 20 µl of K proteinase and 200 μl of AL buffer at 56ºC, 
for 10 minutes. DNA precipitation was performed by adding 200 μl 
of ethanol (96%). DNA was eluted in 200 μl of AE buffer and stored 
at -20ºC until further use.
To determine extracted DNA quality and quantity, each DNA 
was analyzed by electrophoresis on a 1% agarose gel, stained with 
blue green loading dye (LGC) (Figure 1).
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figurE 1 – Agarose gel (1%) stained with blue green loading dye showing gel electrophoretic 
profile for DNA integrity
DNA: deoxyribonucleic acid; L: ladder; 1-15: DNA samples.
As an intern control of the reaction, samples with DNA 
were subjected to PCR for human β-globin gene amplification, 
using PCO3 (5’CTTCTGACACAACTGTGTTCACTAGC3’) and PCO4 
(5’TCACCACAACTTCATCCACGTTCACC3’) oligonucleotides, which 
flanks a sequence of about 110 pb (Figure 2). Reagents quantities 
and concentrations were just the same as PCR reaction for HPV, 
using MY oligonucleotide primer (Table 1).
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Samples that were positive for human ß-globin gene were 
subjected to DNA viral of HPV research. It was excluded from the 
analysis only negative samples for ß-globin gene, after reanalyzing 
samples for confirmation.
DNA amplification
Two different pairs of oligonucleotides primers were used in 
this study to HPV detection: MY09/MY11, GP5+/GP6+ (Figures 
3 and 4). PCR reactions for each oligonucleotide primer were 
carried out separately, as previously described by Bernard et al.(3) 
and De Roda-Husman et al.(6). Table 1 shows the oligonucleotides 
primers used in PCR, as well as their amplification conditions. 
For each PCR reaction, it was used a positive control (DNA 
extracted from a condyloma sample) and a negative control 
(H
2
O). Result was considered positive for DNA-HPV when one of 
the MY09/MY11 or GP5+/GP6+ oligonucleotides primers testing 
detected the viral DNA.
HPV detection using primers MY09/MY11 and GP5+/GP6+ in patients with cytologic and/or colposcopic changes
figurE 2 – Agarose gel (1,5%) stained with blue green loading dye showing PCR 
electrophoretic profile using PCO3/PCO4 oligonucleotide primers for human ß-globin gene 
detection corresponding to ~110 pb
PCR: polymerase chain reaction; L: ladder; C+: positive control; 1-6: positive samples;
7: negative sample; C-: negative control. 
figurE 3 – Agarose gel (1,5%) stained with blue green loading dye showing PCR 
electrophoretic profile using MY09/11 oligonucleotide primers for HPV-L1 gene detection 
corresponding to ~450 pb
PCR: polymerase chain reaction; HPV: human papillomavirus; L: ladder; C+: positive 
control; 1, 6, 10, 15: positive samples; 2-5, 7-9, 11-14: negative sample; C-: negative control.
figurE 4 – Agarose gel (1,5%) stained with blue green loading dye showing PCR 
electrophoretic profile using GP5+/GP6+ oligonucleotide primers for HPV-L1 gene detection 
corresponding to ~150 pb
PCR: polymerase chain reaction; HPV: human papillomavirus; L: ladder; C+: positive 
control; 1-6: positive samples; C-: negative control.
tABLE 1 – Genetic oligonucleotide primers used for DNA of HPV detection





450 pb 15 mM MgCl
2 
(buffer 1×), 800 µM of dNTPs, 50 
pmol/µl of each oligonucleotide primer, 1.25 U from 











150 pb 15 mM MgCl
2 
(buffer 1×), 800 µM of dNTPs, 50 
pmol/µl of each oligonucleotide primer, 1.25 U from 







DNA: deoxyribonucleic acid; HPV: human papillomavirus; PCR: polymerase chain reaction; dNTP: deoxyribonucleotides phosphate.
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Statistical analysis
For data statistical analysis we used chi-squared and/or 
Fisher’s exact test, through SPSS software (Chicago, IL, USA), 16.0 
version, considering significant variables those that reached p < 
0.05 in the two-tailed test.
 
rESuLtS
A sample survey of cytological and/or colposcopic abnormalities 
cases diagnosed during May 2009 and March 2011 was performed 
at the Clinic of Gynecology of NASF, in the city of Penedo-AL. The 
average age of the studied population was 36 years (range: 18-58 
years). Regarding cytologic results, 21 patients (30%) showed ASC-US; 
20 (29%), AGUS; 12 (17%), LSIL; and five (7%), HSIL. Twelve patients 
(17%) showed positive colposcopy (Figure 5 and Table 2).
figurE 5 – Results of cytological and/or colposcopic reports from cervical samples of 
patients admitted in the city of Penedo-AL (2009-2011)
ASC-US: atypical squamous cells of undetermined significance; AGUS: atypical glandular 
cells of undetermined significance; LSIL: low-grade squamous intraepithelial lesions; HSIL: 
high-grade squamous intraepithelial lesions.




n = 27 (100%)
GP5+/GP6+
n = 27 (100%)
p* value
Negative 23 (85%) 19 (70%) 0.3261
Positive 4 (15%) 8 (30%)
*: Pearson’s chi-square test.
DNA: deoxyribonucleic acid; HPV: human papillomavirus; n: number of collected samples.
May 2009 to May 2011
n = 70 (100%)
ASC-US
n = 21 
(30%)
AGUS
n = 20 
(29%)
LSIL







n = 12 (17%)
tABLE 2 – Correlation between diagnostic categories to cytologic and colposcopic examinations and HPV molecular detection
Cytological and/or 
colposcopic changes
HPV negative HPV positive* Total p** value
n % n % n %
ASC-US 5 18.5 1 3.7 6 22.2 0.4183
AGUS 8 29.6 2 7.4 10 37
LSIL 4 14.8 3 11.1 7 26
HSIL 0 0 1 3.7 1 3.7
Colposcopic changes 2 7.4 1 3.7 3 11.1
Total 19 70 8 30 27 100
*: HPV positive means the sum of the two PCR methods used; **: Fisher’s exact test.
HPV: human papillomavirus; ASC-US: atypical squamous cells of undetermined significance; AGUS: atypical glandular cells of undetermined significance; LSIL 
low-grade squamous intraepithelial lesions; HSIL: high-grade squamous intraepithelial lesions; PCR: polymerase chain reaction.
Only one patient has HSIL and a positive sample to HPV, 
which demonstrate the effectiveness of PCR as standard molecular 
method. From the seven patients with LSIL, only three were positive 
for o HPV. The most likely possibility is that the results for the other 
four samples were false negative.
Results showed that DNA of HPV was detected in 15% and 30%, 
using MY-PCR and GP+-PCR, respectively. There was no statistical 
difference between the two oligonucleotides used in PCRs (Table 3).
 
DiSCuSSion
PCR is being increasingly used in clinical laboratories to HPV 
diagnose. For the L1 region, there is consensus in indicating two 
oligonucleotides primers systems commonly used: MY09/MY11 
and GP5+ /GP6+. Both detect a wide range of HPVs. Degenerated 
MY09/MY11 oligonucleotide primer uses annealing high 
temperature (55ºC) and can amplify multiple HPV infections. 
However, GP5+/GP6+ oligonucleotide primer has lower annealing 
temperature (42ºC), allowing the best amplification of single HPV 
infections, when compared to multiple infections(18). 
Studies in the literature indicate variables rates of HPV 
detection. This differences in detecting DNA of HPV suggest a 
potential difference in the ability to amplify fragments of different 
sizes and specific types of HPV, depending on the methods used 
for DNA detection, and may also de due to the types of studied 
material (smears, frozen material, paraffin material), anatomical 
localization, population issue, and design of oligonucleotides(5).
Emanuella Meneses Venceslau; Mauro Muniz Bezerra; Anna Carolina Mota Lopes; Érick Vieira Souza; Alexandre Sherlley Casimiro Onofre; 
Claudia Moura de Melo; Verônica de Lourdes Sierpe Jeraldo; Fabiana Botelho de Miranda Onofre
284
rESuMo 
Introdução: O câncer cervical é uma das doenças mais frequentes entre mulheres, e causa considerável morbidade e mortalidade. 
Com base nos fatos de que o câncer cervical é uma neoplasia importante no nordeste brasileiro, e que a prevalência do papilomavírus 
humano (HPV) de alto risco está diretamente associado a ele, este trabalho teve como objetivos correlacionar os achados citológicos 
e/ou colposcópicos com status de infecção de HPV e verificar o desempenho dos iniciadores MY09/MY11 e GP5+/GP6+ para detecção 
do HPV. Material e métodos: Os pacientes deste estudo foram de Penedo-AL, uma cidade com elevado nível de pobreza (índice de 
pobreza de 60,62%). Do total de 70 pacientes com alterações citológicas e/ou colposcópicas, 32 aceitaram participar do estudo. 
Resultados: Com relação a citologia, 21 (30%) pacientes apresentaram células escamosas atípicas de significado indeterminado 
(ASC-US); 20 (29%), células glandulares atípicas de significado indeterminado (AGUS); 12 (17%), lesão intraepitelial de baixo 
grau (LSIL); cinco (7%), lesão intraepitelial de alto grau (HSIL); e 12 (17%), colposcopia positiva. Destas, 27 (84%) apresentaram 
banda do gene que codifica para ß-globina humana. Das 27 pacientes, oito (30%) apresentaram positividade para o HPV. Os 
resultados mostraram que o ácido desoxirribonucleico (DNA) do HPV foi detectado em 15% e 30%, usando MY-PCR e GP +-PCR, 
respectivamente. Conclusão: Este estudo sugere que mais de um tipo de iniciador de oligonucleotídeo deve ser utilizado em 
amostras clínicas para aumentar a sensibilidade na detecção do HPV.   
Unitermos: câncer cervical; citologia; colposcopia; HPV; PCR.
In this study we observed a greater number of positive samples 
using GP5+/GP6+ oligonucleotides, when compared to MY09/
MY11. From 27 samples, eight (30%) were positive for HPV. DNA-
HPV was found in 15% and 30%, using MY e GP+ oligonucleotides 
primers, respectively. From these, four (15%) were detected by both 
methods, and eight (30%), only by PCR do GP+. However, there was 
no statistical difference between the two oligonucleotides used in 
PCRs (p = 0.3261), even with twice detection efficiency using GP+ 
oligonucleotides primers. According to Poljak et al.(17) and Vince 
et al.(25), one cannot rule out the possibility of false negative in PCR 
due to DNA-HPV low concentration in the clinical sample and the 
presence of PCR endogenous inhibitors or from sample processing.
In a Zehbe and Wilander study (26), they compared the sensitivity 
of these oligonucleotides primers for PCR in cervical biopsies 
classified as cervical intraepithelial neoplasia (CIN) I to III. The 
authors demonstrated that the two oligonucleotides primers systems 
were equally sensitive, with a correlation of 98%. Using GP5+/GP6+, 
the authors found HPV positivity of 95% with MY09/MY11 of 94%. 
QU et al.(18), compared the detection rates of the same 
oligonucleotides primers used in our experiment (MY09/MY11 
and GP5+/GP6+) in cervicovaginal washing sample, they found 
DNA of HPV in 45,5% and 42,8%, respectively, with no statistical 
difference between the two oligonucleotides used in PCRs, only in 
the evaluation of HPV types detected by each pair of oligonucleotide, 
result similar to ours, which also showed no statistical difference.
Remmerbach et al.(19), through oral mucosal smears analysis 
of patients suspected of carcinoma lesions, showed that DNA-
HPV was detected in 2.8% of sample using PCR with MY09/MY11 
oligonucleotides and 35,8% with GP5+/GP6+ oligonucleotides. 
These authors also reported that HPV detection with GP5+/GP6+ 
oligonucleotides was higher than MY09/MY11 oligonucleotides, 
corroborating the results found in our study. This can be explained 
by the smaller size of DNA fragment amplified by GP-PCR system. 
Thus, this oligonucleotide would have greater efficiency in HPV 
detection in samples with fragmented DNA. These authors also 
found a greater HPV detection in biopsy samples, when compared 
to cervical smear sample, which may indicate the difference 
between our study and the Zehbe and Wilander study(27).
Iftner and Villa(15) reported that the sensitivity and specificity 
of PCR method may vary depending mainly on the choice of 
oligonucleotides primers used, the number of base pairs of the 
product amplified by PCR, performance of DNA polymerase used 
in the reaction, DNA-HPV type spectrum amplified, and the ability 
to detect different types in the infection. Studies in the literature 
indicate variables HPV detection rates. 
The choice of suitables oligonucleotides to clinical and 
epidemiological uses should consider the source of clinical 
material, the size of PCR product, range of DNA-HPV types to be 
amplified, oligonucleotides ability to amplify the HPV multiple 
types and the availability of sequencers systems or specific probes 
to identifying the different HPV genotypes(5). 
ConCLuSion
Considering the great intra- and inter-observer variability 
associated to cytological interpretation of preneoplastic and 
neoplastic cervical lesions, the use of molecular detection methods, 
such as PCR technique, becomes an important tool in identifying 
patients with HPVs responsible for developing cervical neoplasia, 
thus supporting medical management. This study suggests that 
more than one type of oligonucleotide primer should be used in 
clinical samples to increase the sensitivity in HPV detection.
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